Care of the Adult Critically Ill COVID-19 Patient
Annex D

Provincial Critical Care Adult COVID-19 Working Group

Critical Care Strategic Clinical Network Alberta Health Services

Note: This document adapts prior pandemic and Influenza-Like Illness (ILI) guidance to the current COVID-19 crisis. This document has been developed by the Provincial Critical Care Adult COVID-19 Working Group.

Intention for use:
- To guide all providers of critical care in Alberta as to the basic care of adult critically ill patients with suspected, probable or confirmed COVID-19 infection to ensure such patients receive optimal, consistent and equitable care throughout the ICUs of Alberta.
- Recognize that the application of the guidance in this document will need to be adapted to the characteristics of each individual unit, zone and department.
- This guideline is not meant to be applied to patient groups outside of critical care units.

AHS COVID-19 Website
# Table of Contents

Table of Contents ............................................................................................................ 2  
Surveillance ..................................................................................................................... 6  
Admission of COVID-19 Patients to Critical Care ............................................................ 7  
Laboratory Testing .......................................................................................................... 9  
Staffing Considerations ................................................................................................. 13  
Infection, Prevention and Control .................................................................................. 13  
General ICU Care .......................................................................................................... 16  
Code Blue Resuscitation of the Suspected, Probable or Confirmed Positive COVID-19 Patient ................................................................................................................................. 18  
Respiratory Care ........................................................................................................... 22  
Medical Care ................................................................................................................. 27  
REMAP-CAP Trial: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial ................................................................................................................................. 29  
Handling of Patient Care Items and Equipment ................................................................ 31  
Environmental Cleaning ................................................................................................. 32  
Appendix A .................................................................................................................... 33  
Appendix B .................................................................................................................... 34  
Appendix C .................................................................................................................... 35  
Appendix D .................................................................................................................... 37  
Appendix E .................................................................................................................... 40
Disclaimer:

This material is intended for general information only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. AHS staff who require legal advice regarding copyright should contact the Corporate & Commercial Division within AHS Legal & Privacy for further assistance. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.

NOTE: The links in this document are updated regularly and should be periodically reviewed.

© 2020 Alberta Health Services, Critical Care Strategic Clinical Network. 
This copyright work is licensed under the Creative Commons Attribution-Noncommercial-NoDerivative 4.0 International. You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, Critical Care Strategic Clinical Network, do not adapt the work and abide by the other license terms. To view a copy of this license, see: https://creativecommons.org/licenses/by-ncnd/4.0/. The license does not apply to content for which the Alberta Health Services is not the copyright owner.
<table>
<thead>
<tr>
<th>Version</th>
<th>Author</th>
<th>Summary of Updates</th>
</tr>
</thead>
</table>
| March 11, 2020   | CCSCN with Provincial Critical Care COVID-19 Working Group              | • Suspected or confirmed COVID-19 added throughout  
• Negative pressure rooms preferred if available  
• Updates to charting for code blue  
• PPE reminders for visitors  
• Delete reference to use of airborne isolation rooms if available  
• Changed guidance on humidity to:  
  o “Avoid use of heated humidity systems other than when they are fixed integral systems of a particular ventilator”  
  o “Humidity should be preferentially provided via in-line HME devices. Active/heated humidity systems should only be used when necessary (e.g., to manage difficult secretions or to provide inhaled epoprostenol) and only when such a system is part of a fixed integral part of a particular ventilator”  
• Replace prostacyclin with epoprostenol |
| March 14, 2020   | Zuege, based on feedback from Provincial Working Group                  | • Extubation added to AGMP  
• Addition of cohort resources from Infection Prevention & Control (IP&C)  
• Diagnostic imaging considerations and guidance on patient care rounds added to general care section  
• Updates to IP&C section  
• Updated lab testing  
• Updates to visitation policies  
• Code Blue changes per Provincial working group  
• Addition of extubation guidelines  
• Revisions per LSE for patient care items, equipment and environmental control  
• Medical care updates  
• Additions of intubation resources, proning resources and PPE conservation |
| April 13, 2020   | Robertson/Morrissey/Bagshaw/Zuege based on feedback from Provincial Working Group, feedback from the provincial critical care community and updated AHS Guidance documents. | • Updated screening criteria – inclusion of ongoing monitoring  
• Addition of AGMP guidance tool and updated IP&C COVID-19 Recommendations  
• Updated visitor policies  
• Removal of door being left shut for settle time based on updated IP&C guidance  
• Updated medical treatment guidelines – changed recommendations on steroid usage  
• Code blue changes to charting section |
<p>| July 9, 2020     | Blythe/Robertson/Bagshaw/Zuege                                        |                                                                                                                                                   |</p>
<table>
<thead>
<tr>
<th>Date</th>
<th>Authors</th>
<th>Changes</th>
</tr>
</thead>
</table>
| Dec 14, 2020 | Robertson/Blythe/Bagshaw/Zuege   | • Changing of presumptive/presumed to probable to align with AHS case definitions  
• Disclaimer and copyright added  
• Removal of AGMP list and link to AGMP tool  
• Updated Code Blue section  
• Updated provincial lab testing requisition  
• Added guidance on repeat COVID positive testing  
• Updated PPE guidance, continuous masking  
• Updated transport guidance aligning with IPC recommendations  
• Updated Environmental and Handling of Patient Supplies Sections per IP&C  
• Addition of compassionate exemptions for visitation policies  
• Addition of virtual presence of patient and family on rounds  
• Addition and updates of several AHS Rapid Response reports and evidence—Awake Proning, O₂ Therapy, Video Laryngoscopy, Corticosteroids  
• VTE Prevention |
| Dec 20, 2020 | Zuege/Bagshaw                    | • Revise wording and emphasis of critical care intended audience  
• Revise wording around use of HHHF, awake pruning and non-invasive ventilation |
| Feb 17, 2021 | Robertson                        | • Reformatted  
• Appendix C version update  
• Updated guidance on discontinuation of precautions  
• Ensured all links contain most updated information  
• Additional information added to general care on nutrition in the ICU  
• Additional information on variants of concern, lab results and cohorting recommendations  
• Additional PPE supports for family/visitors  
• Guidance on use of tocilizumab |
Surveillance

Case Description for COVID-19

COVID-19 is an infectious syndrome caused by SARS-CoV-2, a novel coronavirus. COVID-19 is believed to be spread primarily via respiratory droplets (similar to influenza and other coronaviruses such as MERS and SARS) and/or contact (e.g., contaminated hands to mucous membranes). Numerous genetic variants of SARS-CoV-2 are now known to exist in addition to the original ‘wild’ type. Some variants may have differences in transmissibility and/or pathogenicity.

Clinical Presentation
• Individuals infected with the virus that causes COVID-19 may have few or no symptoms and may range from mild to severe, life-threatening illness, with manifestations including fever greater than 38°C (>90% of cases), new onset or exacerbation of chronic cough (80% of cases), shortness of breath (20% of cases), difficulty breathing, sore throat or runny nose. Canadian SPRINT-SARI Characteristic Data March 2021
• Severe disease from COVID-19 infection can cause viral pneumonia and respiratory failure, sepsis, septic shock and multi-organ failure or death.
• Susceptibility is assumed to be universal.
• The virus appears to cause more severe disease in older adults (greater than 60 years of age) and individuals with underlying comorbidities (e.g., cardiovascular, renal and liver disorders, diabetes and chronic respiratory diseases) or immune compromising conditions.
• There is evolving understanding of the immune response in COVID-19 disease, and the possibility of reinfection with SARS-CoV-2 has not been excluded.

Department Standard Operating Procedure

COVID-19 Screening and Monitoring Criteria:

Click links to see the most current updated screening and testing criteria for COVID-19:

AHS Directive: Communicable Diseases (respiratory including COVID-19 and ILI) Screening, Assessment and Monitoring in Acute Care

Patient Screening and Symptom Assessment & Monitoring Recommendations for COVID-19

• All patients are to be assessed initially for symptoms and risk factors associated with respiratory communicable disease using Form 21615: Communicable Disease (Respiratory) Initial Screening Form (or equivalent electronic version).

• The initial assessment will then inform the use of AHS Acute Care COVID-19 Expanded Testing Algorithm.
Ongoing assessment of admitted patients is to be completed using Form 21616: COVID-19 Symptom Identification and Monitoring or equivalent electronic version. Note: electronic versions do not have same form numbers or titles as paper versions

COVID-19 Testing and Self-Isolation Criteria

Admission of COVID-19 Patients to Critical Care

1. Patients who are suspected, probable or confirmed positive COVID-19 status admitted to the ICU will be cared for using contact and droplet precautions.

Respiratory Illness: Assessing the Need for Additional Precautions (Isolation)

2. A point-of-care risk assessment (PCRA) must be performed before every patient interaction with a suspected, probable or confirmed positive COVID-19 status irrespective of location. The PCRA should include the frequency and probability of routine or emergent aerosol generating medical procedures (AGMP) being required.

AHS Point of Care Risk Assessment (PCRA)

3. N95 respirators or approved equivalent protection must be used by all health care workers in any patient care area where aerosol generating medical procedures (AGMP) are being performed, are frequent or probable (e.g. ventilator disconnection), or with all suspected, probable or confirmed positive COVID-19 intubated patients.

4. A current list of AGMP can be found here: Aerosol Generating Medical Procedure Guidance

Aerosol generating medical procedures (AGMP) require an N95 respirator if the patient has a suspected or confirmed acute viral respiratory infection. This includes viral respiratory pathogens such as influenza A or B or other common seasonal respiratory viruses including respiratory syncytial virus, rhinovirus, enterovirus, adenovirus, human metapneumovirus, non-COVID coronavirus, and parainfluenza virus; novel pathogens such as COVID-19, SARS, MERS-CoV, avian influenza; and for suspected or confirmed viral hemorrhagic fever.

When an AGMP is in progress the following poster may be utilized: AGMP Poster

**There is no settle time required after AGMP is complete**

5. Due to the high risk of aerosol generation, critically ill patients with suspected, probable or confirmed positive COVID-19 will be admitted to single patient rooms when available.
6. Negative pressure (airborne isolation) rooms are not required and should be reserved for patients with disease processes requiring airborne isolation but may be utilized if available.

7. If all single patient rooms are occupied, then attempt to cohort COVID-19 patients in one area with a minimum 2-meter separation between patients. IP&C guidance on cohorting of patients should be reviewed.

Of note, given the presence of SARS-CoV-2 variants, before considering cohorting patients with COVID-19 in the same room, the viral subtype must be identified (eg wild type or variant) for both patients being considered for cohorting. Viruses from all COVID-positive patients in Alberta are being subtyped with turn-around times currently being approximately 6 days. Viral subtyping results are not currently available within existing electronic medical records (though this is being actively explored).

- Strain typing of COVID-19 must be considered when cohorting.
- Patients with unknown COVID-19 strain are not to be cohorted.
- Variant and non-variant ("wild type") strain COVID-19 patients are not to be cohorted

IP&C Cohorting Recommendations for COVID-19 in Acute Care

IP&C Recommendations for Cohorting Inpatients on Additional Precautions in Acute Care Facilities

8. Close room doors with enough of an opening to allow for hearing in-room alarms. Keep doors closed fully during AGMPs.

9. Stock isolation cart with adequate supply of N95 respirators (all brands and sizes), goggles, face shields, gloves (all sizes), isolation gowns, surgical masks and disinfectant wipes. Ensure the entire spectrum of brands and sizes of N95 masks are available and placed on the isolation cart outside of the patient room and at the entry to a COVID-19 cohort area. Ensure disinfectant wipes are located inside and outside the patient room and cohort areas and are adequately full. Refer to sections K and L in this document for environmental and equipment cleaning processes.

10. Enter order for “Contact and droplet isolation precautions” in the patient record, adding the comment “Use N95 respirators for aerosol generating medical procedures, and for all suspected, probable or confirmed positive COVID-19 patients receiving heated humidified high flow oxygen delivery non-invasive ventilation or invasive mechanical ventilation” as additional information.


12. Post the AHS Contact and Droplet Isolation Sign.
13. Ensure appropriate viral diagnostic tests have been performed prior to admission to ICU (see Section C). If viral diagnostic studies have not been performed – consult with MRHP to order appropriate studies.

**Laboratory Testing**

**Diagnostic studies:**

Though nasopharyngeal swabs (NPS) are commonly used for screening for infection with respiratory viruses, molecular viral studies on sputum samples (e.g., endotracheal aspirates (ETA) or tracheal aspirates) are more sensitive. Molecular tests for respiratory viruses are highly specific hence repeated/confirmatory testing of patients with positive results is not required.

1. Patients with a positive result by molecular testing for respiratory viruses including COVID-19 do not require additional respiratory viral testing.

   *Change in ordering Respiratory Pathogen Panel (RPP) and COVID-19 testing*

2. As of February 3, 2021, ProvLab has been prospectively testing all COVID-19 positive samples for SARS-CoV-2 variants of concern. Turn-around times for subtyping are currently approximately 6 days. Viral subtyping results are not currently available within existing electronic medical records (though this is being actively explored).

   *SARS-CoV-2 Variants of Concern*

3. For patients without a positive result by molecular testing for respiratory viruses including COVID-19:
   i. If an NPS is already collected, do not collect an additional NPS.
   ii. If the patient is intubated, an ETA should be collected as soon as possible and sent for respiratory viral testing (irrespective of whether an NPS has been collected).

4. If the patient is not intubated and has not had an NPS sent for respiratory viral testing, then an NPS should be collected as soon as possible.

5. If there is a clinical possibility of other more unusual pathogens (e.g., as in an immunosuppressed patient), consideration should be given to performing bronchoalveolar lavage (BAL) recognizing that bronchoscopy is an aerosol generating medical procedure (AGMP).

6. Bronchoscopy solely for the purposes of microbial sampling in an otherwise uncomplicated patient is not recommended.
7. If necessary, bronchoscopy should be performed only on intubated patients and used only exceptionally in non-intubated patients with known or suspected COVID-19 to minimize the risk of aerosolization.

8. Some patients infected with COVID-19 may shed virus intermittently and consideration should be given to repeating viral studies if the initial samples are negative in a patient with a high clinical suspicion of COVID-19 or if there was concern that samples may not have been collected appropriately.

9. Reinfection and Repeat Positive COVID-19 Test Results:
   • There is emerging evidence to suggest repeat positive COVID-19 tests after a confirmed patient’s symptoms have resolved represent ongoing shedding of non-viable virus that do not pose a transmission risk.
   • If patient is presenting with positive test after resolution of symptoms, consult with IPC regarding requirements for ongoing additional precautions.
   • Repeat COVID-19 testing is not generally recommended for resolved (cleared) patients within 90 days of the initial positive test result. However, if new symptoms develop within 90 days, testing for other pathogens should be considered based on clinical and risk factor assessment.
   • Repeat COVID-19 testing may be indicated if there is a high risk of re-infection; refer to Alberta Health Novel Coronavirus (COVID-19) Public Health Disease Management Guideline or contact IPC for more information.

10. As viral pathogens are only one diagnostic possibility for most clinical presentations, additional testing should be obtained in the patient presenting with possible but not proven COVID-19 to look for other pathogens.

   At a minimum this would generally include:
   i. blood cultures
   ii. endotracheal or tracheal aspirate for cultures (i.e., bacterial, fungal, PJP etc. as appropriate) (if intubated) or expectorated sputum for culture (if not intubated). Sputum induction is not recommended to reduce aerosol-related infectious risk.
   iii. liver function tests and enzymes
   iv. urinalysis
   v. sampling of pleural fluid if present in significant quantities

11. Consider performing serum LDH, D-dimer, C-reactive protein, ferritin, creatine kinase and, BNP and/or troponin if clinically indicated and not already done.

12. CT scans of the thorax are not suggested solely for the assessment of suspected or confirmed viral pneumonia given lack of specificity, added risk and PPE use needed for transport. CT imaging may be appropriate for other indications.
Nasopharyngeal Swab (NPS):

Collect NPS according to Alberta Precision Laboratories (APL) and Public Health Laboratory recommendations. Mark sample as STAT. Order both COVID-19 and Respiratory Pathogen Panel for the same sample (only a single sample is required for all respiratory viral testing). Send sample to lab.

How to Collect an NPS using a Flocked Swab

How to Collect an NPS using APTIMA Unisex Collection Kit

Endotracheal Tube Aspirate (ETA)/Tracheal Aspirate:

Collect ETA (intubated patients) or tracheal aspirate (for patients with a tracheostomy) and place minimum 0.5-1 ml of secretions into sterile leak proof container. No additional transport medium is required. Mark sample as STAT. Order both COVID-19 and Respiratory Pathogen Panel for the same sample (only a single sample is required for all respiratory viral testing). Send sample to lab.

Bronchoalveolar Lavage (BAL) Fluid:

Collect and send per site Policy and Procedure. Mark sample as STAT. Order both COVID-19 and Respiratory Pathogen Panel for the same sample. No additional transport medium is required. Bronchoscopy is generally to be avoided for the sole purpose of diagnosis of viral pneumonia given higher risk for aerosolization but may be indicated in immunosuppressed patients who may be at risk for multiple and/or unusual organisms. Clinical specimens should be placed in a separate biohazard bag and sealed with the zip lock closure. Ensure that the outside of the bag remains uncontaminated.

Lab Ordering and Results:

1. Expedited Testing and Turn-around Times

2. Sites using Connect Care or Sunrise Clinical Manager (SCM) can order COVID-19 testing directly.

3. Sites not using Connect Care or Sunrise Clinical Manager should request testing manually using the provincial form below. Sites using Connect Care or Sunrise Clinical Manager can utilize this form during downtime.

Provincial COVID-19 and Other Respiratory Viruses Requisition

4. Look for the results of viral testing in Alberta Netcare. Results will also be reported in Sunrise Clinical Manager and in Connect Care.

5. Reporting COVID-19 variant of concern test results.
Transport of COVID-19 Critical Care Patients

1. Notify the receiving area, before departure, of the need for Contact & Droplet Precautions & if an AGMP is in progress or if intubated, for fit tested N95.

2. Follow Form 21628: Intrafacility Patient Transport Checklist for Patients on Additional Precautions to determine PPE required during transport.

3. All health care providers involved in transport must use appropriate isolation precautions. For intubated patients and those with active AMGPs underway (e.g., open suctioning), staff involved in the transport should don N95 respirators. In the absence of the above conditions, surgical masks should be worn.

4. Staff providing direct care during the transport should also don protective eye wear, masks, gown and gloves. Note: personal eye wear is not sufficient.

5. Hand hygiene should be performed before and after patient transport.

6. Wipe the handles of the bed before transport with disinfectant wipes. Designate one porter/assistant as ‘clean’ to open doors and touch elevator buttons.

7. Transport with minimum number of people necessary - registered nurse (RN), registered respiratory therapist (RRT), MRHP, and health care aide (HCA) as appropriate. Follow site specific policies if family members are present.

8. If patient is intubated:
   b. Use of transport ventilators (with filtering systems) is preferred to minimize the need for manual bagging. If use of a transport ventilator is not possible, use a manual bagging unit (with PEEP valve).
   c. RRT will manage airway and oxygen requirements.
   d. Clean and disinfect transport ventilator after use and discard breathing circuit.

9. If patient is not intubated:
   a. Transport with non-humidified (dry) oxygen supply - respiratory to identify the most appropriate oxygen delivery mask.
   b. Patients receiving oxygen by any type of nasal cannula should be given a procedure mask to wear if tolerated.

10. Clean O2 cylinder(s) and transport stretcher with disinfectant wipes before returning to general circulation.
Staffing Considerations

The principle is to minimize the number of staff involved directly with the patient while providing quality patient care.

1. The nurse in charge and the respiratory therapy supervisor are responsible to determine patient assignments and will coordinate care of all patients in the unit with the principle in mind that the total number of staff caring for a COVID-19 patient should be kept to a minimum. If possible, cohort staff so that RNs and RRTs caring for COVID-19 patients are not caring for non–COVID-19 patients. Geographical cohorting of COVID-19 patients may assist with staff assignments if appropriate to facilitate.

2. All members of the healthcare team, inclusive of MRHP, NPs, RNs, RRTs, allied health, and support staff will continue to perform their usual duties. They must review and adhere to all appropriate isolation precautions prior to entering rooms.

3. For students (medical or otherwise) working within an ICU, please check with current educational institution guidelines for any restrictions to practice or exposures.

4. Individuals who are unable to competently adhere to the IP&C recommendations for COVID-19 (e.g., skin condition that precludes proper hand hygiene practices) should not provide care to patients who are under investigation for COVID-19, or those who have suspected, probable or confirmed COVID-19. Staff who are unable to be Fit Tested for N95 respirators should not care for COVID-19 patients that are intubated or those that require any AGMP.

5. During a pandemic there may be a need to move towards team-based models of care delivery during surge. Although the structure of each team model (staff mix, staff to patient ratio) are site specific, there are common facilitating elements to team based model functionality.

Resources for Team-Based Care Models during Pandemic

Infection, Prevention and Control

Suspected, probable or confirmed positive COVID-19 cases in the ICU should be managed with contact and droplet precautions. Use N95 respirators for all aerosol generating medical procedures (Aerosol Generating Medical Procedure Guidance Tool) and for all suspected, probable or confirmed positive COVID-19 intubated patients.

Interim IPC Recommendations COVID-19
1. All staff providing care must be successfully N95 fit tested and masks must be seal checked when applying.

2. Continuous masking and eye protection must be adhered to in patient care areas.

3. **PPE for Family/Support Person(s), Visitors and Patients**

4. AHS PPE task force encourages staff to use AHS provided supplies and encourages staff to not introduce outside PPE into care environments. If you chose to bring your own supply:
   - All personal PPE must be health care grade.
   - Cloth masks are not permitted in Critical Care.
   - Regular eyeglasses do not meet the requirements of eye protection.
   - Staff who choose to bring in their own eye protection are responsible to ensure that they meet Workplace Health & Safety requirements. Staff are responsible to cover the cost, replacement, and disinfecting.

   **AHS PPE Taskforce Guidance: Bringing my own PPE to work**

5. PPE buddy system is recommended when possible.

6. Wear new PPE to enter patient room or bed space.
   - If continuous masking, same mask can be worn into the patient’s room or bed space.
   - Healthcare workers are to wear Contact and Droplet PPE (procedure/surgical mask, eye/face protection, gown, gloves) even if the patient is wearing a mask. Fit tested N95 is only required with AGMP or intubated patients.
   - Remove soiled PPE as soon as possible using proper doffing process.
   - Do not wear PPE outside a patient room or bed space unless transporting contaminated items.

7. Change gloves between care activities for the same patient (e.g., when moving from a contaminated body site to a clean body site).
   - Sterile gloves are for sterile procedures.

   **Best Practice Recommendations: Glove Use and Selection**

8. When an AGMP is in progress the following poster may be utilized: [AGMP Poster]
   
   **There is no settle time required after AGMP is complete**

9. Remove soiled PPE as soon as possible. Change mask when it becomes moist or soiled.

IPC COVID-19 PPE Recommendation for Preservation and Reuse of Eye Protection

11. Use of a dedicated reusable stethoscope is preferred. When not available refer to IP&C guidance document.

Stethoscope Use for Contact and Droplet Precautions including COVID-19 Patients

12. Effective and appropriate use of PPE will keep staff uniforms and clothing clean. Staff should change before leaving healthcare facility and take soiled clothing home in a bag. Soiled uniforms/clothing do not need any special handling in the laundry.

Healthcare Attire Information Sheet
Staff Tips: COVID-19 Personal Clothing and Cleaning Surfaces

13. Hand washing is critical to prevent spread of COVID-19. Special attention to hand hygiene is essential for staff, patients and visitors; wash hands with soap and water or use antiseptic hand rub before and after each and every contact with patients or their environment. Remind colleagues if you see lapses in hand hygiene behavior. Educate patients and visitors about how and when to use hand hygiene products.

Hand Hygiene Education

14. Discontinuation of Isolation for patients with suspected or confirmed COVID-19 infection in critical care units:

Discontinuation of Contact and Droplet Precautions for Suspected or Confirmed COVID-19 Patients in Critical Care

For patients with suspected or probable but not confirmed COVID-19 infection, maintain contact and droplet isolation precautions including fit tested N95 respirators for AGMP and intubated patients until the COVID-19 AND full respiratory pathogen panel results are confirmed on all respiratory samples sent (ETA, NPS and BAL). If any results are positive – maintain current precautions.

PPE Guidance:

The following link contains all up to date information on PPE and should be reviewed periodically: Personal Protective Equipment (PPE).

Applying N95 respirators: All health care workers must have been fit tested within the last two years. Hold mask in your hand and pull both elastic ties, bottom first, over your hand for ease of putting mask on. Test to ensure that mask is secure and that there are
Care of the Adult Critically Ill COVID-19 Patient

no leaks. Discard immediately outside of room after use. Do not touch the outside of the mask while discarding as it is considered contaminated.

**Proper wearing of an N95 respirator includes:**
- Putting on the respirator before entering the patient’s room.
- Molding the metal bar over the nose.
- Ensuring an airtight seal on the face, over top of the nose and under the chin.
- Donning eye protection after N95 for AGMP.
- Leaving the room and changing the respirator when it becomes moist.
- Removing the respirator after leaving the patient’s room by touching elastic only.
- Not wearing respirator around the neck.

**Personal Protective Equipment (PPE) Guidance to Help Make Continuous Masking Work for You**

**Eye protection (disposable face shields/goggles):** Face shields or goggles are to be worn upon entering the patient room. Personal eyewear (glasses) is not sufficient. Face shields are single use. Discard face shields outside of the room after use. If goggles are re-used they must be fully wiped down with disinfectant wipes prior to re-use.

**Gloves:** Always perform hand hygiene prior to putting on gloves and after removal.

**Gowns:** Remove lab coat before donning. Ensure the back of the gown is secured – do not leave open.

**Donning:** [AHS Donning Poster](#)

**Doffing:** [AHS Doffing Poster](#)

**Meals:** Used meal trays and dishes do not require special handling. Disposable dishes and utensils are not required.

**General ICU Care**

1. Reduce all clinically unnecessary entries into the room. See [Appendix E](#) for strategies to conserve personal protective equipment (PPE).

2. Patient care rounds should take place outside of patient room to minimize number of people in patient room and preserve PPE. Utilization of virtual family and patient presence via electronic devices should be considered and proactively planned for when family/patient attending patient care rounds at a distance.

[Quality Virtual Care - Virtual Health Tools during COVID-19](#)
3. Patient Room Supplies
   
a. Use disposable supplies wherever possible.
b. Additional supplies should be delivered by a clean staff member to the room
   at the request of the in-room staff.
c. All equipment should be kept in the patient’s room to avoid transmission via
   objects. Dedicate equipment to the patient’s room or clean with hospital grade
   disinfectant after use prior to returning to general circulation.
d. Avoid overstocking rooms – only bring in supplies as required. All items that
   cannot be surface disinfected should be discarded when the patient is
   discharged.

4. Visitors

   For visitation policies during COVID-19 access the following links for up-to-date
   visitation regulations. Follow site specific protocols during family visitation. Many
   documents and posters are available in multiple languages.

   COVID-19 Essential Visitor and Designated Family/Support
   Residents Family Support & Visitation of Patients & Residents
   COVID-19 Visitor Restrictions
   Poster AHS Virtual Visitation -
   FAQ
   MyHealth.Alberta Visitor Contact & Droplet Guidance

   AHS has established a process for persons seeking exemption from quarantine to visit a
   patient who is receiving critical care for a life-threatening illness or imminent end-of-life
   care. Please see the following link for details:

   Compassionate Exemptions COVID-19

5. Charting

   a. Do not take the patient chart or laboratory results into the patient room.
b. Mobile computer terminals must always remain outside the patient room unless
   a dedicated mobile terminal is available to remain in room (e.g., for units
   where dedicated mobile terminals are available for very sick patients requiring
   in-room presence of staff a majority of the time).

6. Investigation Considerations

   a. All attempts should be made to minimize off unit testing unless clinically required.
b. Discontinue daily orders for bloodwork, chest x-ray (CXR) or
   electrocardiograms (ECGs) and only order when clinically required.
c. All CXRs should be performed portably within the ICU.
d. Diagnostic testing should be performed portably in the ICU when possible (e.g. ultrasonography).

e. When possible and where capability exists, utilize bedside RN to perform 12 lead ECG with bedside cables.

7. Nutrition

Following current ICU Enteral Nutrition Guidelines to achieve nutrition adequacy is encouraged. Many patients who arrive to critical care already show signs of malnutrition related to poor intake and inability to eat due to their declining respiratory status and COVID-19 related nutrition symptoms and side-effects (i.e. loss of taste/smell, lack of appetite, fatigue, weakness etc.): screening for malnutrition is essential. Refeeding syndrome is higher risk in this malnourished population. Adequate provision of calories and protein are required to recover from critical illness, especially for patients who have experienced COVID-19. Given use of sedation (propofol) and its caloric contribution, nutritional needs should be discussed with your site dietician.

8. Recovery/Rehabilitation

A knowledge gap exists among non-ICU practitioners related to Post Intensive Care Syndrome (PICS) and ICU delirium. Knowledge and perceptions about ICU survivors are sub-optimal. Many COVID-19 patients specifically will have longer critical care stays. Adequate assessment of needs and handover communication for ongoing patient care is crucial for the successful transition throughout the patient’s stay, both in and out of the ICU. Providing recovery/rehabilitation plans upon ICU discharge that travel with the patient through the healthcare continuum have potential to contribute to improved patient recovery.

Provincial Post-Covid Rehabilitation Taskforce Recommendations

COVID-19 Nutrition for Recovery Handout

Code Blue Resuscitation of the Suspected, Probable or Confirmed Positive COVID-19 Patient

Guidelines for Code Blue Resuscitation of Suspected, Probable or Confirmed COVID-19 Patients In Acute Care

Guiding Principles:

1. Point of Care Risk Assessment (PCRA) should be completed by all health care workers before initiating any resuscitation.
2. The AHS Scientific Advisory Committee has determined that the provision of chest compressions alone is not considered to be an aerosol generating medical procedure (AGMP) and only requires contact and droplet PPE.
3. Assume patient is COVID-19 positive, unless otherwise identified/known.
4. Consideration that the location of resuscitation may influence response and team processes (i.e. Critical Care Unit vs. Inpatient Unit or Emergency Department (ED)).
5. Minimize number of participants in the resuscitation area during resuscitation.
6. Minimize equipment in the resuscitation area wherever possible.
7. If CPR is indicated, chest compressions alone can be initiated safely by a provider wearing contact/droplet PPE.
8. Contact and droplet precautions (including a fit-tested N95 respirator) shall be donned prior to initiating any AGMP (including manual ventilation and airway management) by all response team members, even if there is a perceived delay in resuscitation efforts.
9. Routine practices, such as defibrillation are otherwise unchanged from non-COVID-19 patients.

Communication:

- Current paging/notification processes should be followed.
- Clear identification of isolation requirements should be made to the response team on arrival.
- Clear communication of current GOC status should be made to the responding resuscitation team members on arrival, where available/known.
- Upon arrival to the code, team members should quickly clarify roles and which members will be working inside versus outside the room.

Arrival to Code Blue:

- Ensure that PPE is readily available for responding team members and that there is an available “safety/logistics officer” to monitor donning/doffing. Since the availability of suitable PPE in enough quantities at the site of the arrest may not be guaranteed, the use of PPE pre-made kits should be considered, to travel with the response team or to be stored with code carts (where possible).
- Chest compressions alone are not an AGMP and an N95 respirator is not required to initiate hands-only CPR. Healthcare workers completing manual chest compressions are directed to continue to wear recommended PPE in alignment with our continuous masking directive, the point-of-care risk assessment, with the addition of contact and droplet precautions for patients with suspected, probable or confirmed positive COVID-19.
- Place loose clothing/sheet over the mouth and nose of the patient, as airway source control while awaiting individuals who are wearing PPE including fit-tested N95 respirators.
- CPR with manual ventilation or airway management is an aerosol generating medical procedure. Only individuals who are wearing PPE, including fit-tested N95 respirators should manage the airway.
- Donning should be carried out quickly but meticulously, even if there is a perceived delay to resuscitation. If multiple individuals arrive at the same time, priority for donning and entering the room should be given to the Code Blue team leader and/or airway expert physician, and to the ICU RN (assuming compressors are already in place with appropriate PPE).
Inside the room:

- Code cart with defibrillator and arrest drugs should be brought into the room if feasible and if enough clean carts are available on site. The code cart may be left just outside the resuscitation area and the defibrillator and medication drawer may be removed and passed into the patient’s room upon the resuscitation team’s arrival.
- Intubation equipment:
  - Video laryngoscopy is highly recommended for the first attempt at intubation (where available).
  - Priority should be placed on intubation and obtaining a secure airway with closed ventilation, especially in an unresponsive patient.
  - If the patient has a laryngeal Mask Airway (LMA) in situ, it should be swapped to a cuffed endotracheal tube as soon as possible.
  - If manual bagging of the patient is required because of unsuccessful initial intubation (see below), it should be provided via a bag valve mask with a Heat Moisture Exchange Filter (HMEF).
  - When intubation is successful and manual bagging is required, it should be provided via a bag valve mask with a HEPA filter, capnograph (where available) and include placement of inline suction.
** There is no settle time required after AGMP is complete **
- Suggested response team members:
  - Code Blue Team Leader.
  - Airway expert physician (if available).
  - RRT to assist with intubation and ventilation.
  - RN to administer medications, cardioversion/defibrillation and update code blue team leader regarding changes in cardiac rhythm (ICU RN).
  - Health Care Worker (HCW) to do CPR (1) – Usually first responder.
  - HCW to do CPR (2).
  - RN for documentation and time-keeping.

Outside the room:

- RN/HCW “runner”, to assist with supply of equipment stored on the unit and the activation of other HCWs, if required.
- “Logistic/Safety Officer”, who should be a senior HCW, to regulate access to the patient's room, monitor proper PPE donning and doffing, ensure that protocols and the opening and closing of doors is followed and communicate with the ICU prior to the initiation of patient transport.

Modifications to Advanced Cardiac Life Support (ACLS) in COVID-19 Patients:

- Intubate patients early and hold CPR during intubation to minimize aerosolization of particles and optimize intubation success.
- The best pharmacotherapy for induction and intubation will be determined by the MRHP on a case-by-case basis but in general should include strategies that
minimize chances of cough or aerosol generation via use of agents inducing deep sedation and often use of neuromuscular blockade when clinically appropriate (e.g. no signs predicting difficult intubation).

- Manual bagging of non-intubated patients using a BVM should be avoided if possible. If necessary because of unsuccessful initial intubation, use two experienced practitioners to establish an intact seal and minimize the risk of aerosolization.
- Avoid disconnections between the ETT and resuscitation bag. If required due to gas trapping, the plan to disconnect should be announced loudly in advance and the ETT should only be disconnected beyond the HEPA filter.

Post-Arrest:

- PPE Doffing: DO NOT RUSH. BE METHODICAL. Remove PPE slowly and carefully to avoid inadvertent contamination of yourself or others, performing hand hygiene in between each step while doffing.
- Logistic/safety officer to monitor member PPE doffing.
- Team to decontaminate specialty equipment as per standard routines and IP&C guidelines.
- Discard any opened supplies or any that cannot be cleaned appropriately.

Post ROSC Care

- Ensure adequate and appropriate required staff available before any transportation attempted. Follow site specific policies if family members are present.
- Designate one runner ‘clean’ to pre-scout/secure transport route, open doors and touch elevator buttons.
- If patient is intubated, use of transport ventilators (with filtering systems) is preferred to minimize the need for manual bagging.
- Transportation to a critical care unit should follow guidelines listed in Section D of this document.
- For patients being transported to an ICU or an advanced care unit in a facility, consideration should be given to testing that can be safely completed on route to minimize the need for additional transports (e.g. CT scan).

Charting Considerations:

- Computer code narrator may be utilized with existing computers within the room or immediately outside the resuscitation room.
- No portable computer devices should be brought into the room.
- All efforts to maintain a clean paper chart should be taken.
  - Papers are not a means of transmission. Handle all paper with clean hands, clean any shared items (like chart binders, pens or binders) with a low-level disinfectant wipe.
  - Transcribing for purposes of infection prevention will not be required.
Respiratory Care

The basic principles are to always use personal protective equipment in addition to appropriate isolation precautions and minimize the use of aerosol-generating procedures.

For Non-Intubated Patients:

1. Provide O₂ as ordered with continuous SpO₂ monitoring.
2. For patients receiving oxygen by any type of nasal cannula outside of single rooms should be given a procedure mask to wear, so to reduce others’ exposure to cough/sneeze droplet spread, if tolerated.
3. Patients should be cared for with the head of bed elevated 30-45 degrees.
4. Minimize use of sedative and analgesic therapies (other than for palliative care).
5. No peak flow monitoring.
6. Nebulization should be avoided and be used only as an exception, Memorandum: Restricted use of Nebulized Treatment for Covid-19
7. Bronchodilator delivery via MDI via spacer is preferred if patients can effectively utilize.
8. If patient is on HHHF or NIV, aerosolization should be administered via in-line devices, rather than disconnection and delivery of MDI.
9. The evidence base for the efficacy and safety of awake prone positioning of non-intubated COVID-19 patients with hypoxemic respiratory failure is not well established and hence this practice is not recommended for routine or generalized application in this population of patients in the ICU. This does not preclude the selected use of this procedure based on best clinical judgement. Clinical trials of awake prone positioning are active and enrolling in various facilities in Alberta and consideration for trial participation is strongly encouraged. The following trials are currently underway in Alberta:
   • COVI-PRONE CLINICAL TRIAL
   • CORONA

If this procedure is used, given uncertain efficacy and safety and the observation of significant failure rates with the need for more advanced management, there should be careful consideration of appropriate patient selection (fully awake and cooperative without hemodynamic instability or current signs of impending respiratory failure), initial tolerance and ongoing close monitoring needs. Patients should be closely monitored for evidence of clinical deterioration.

Heated Humidified High Flow Oxygen therapy devices (AIRVO, Optiflow or Vapotherm):

• Aerosolization of respiratory secretions may result from high flow heated humidity oxygen therapy devices and use of this therapy is considered a continuous AGMP.
• The clinical efficacy in clinical trials of heated high flow oxygen therapy to support
patients with significant acute hypoxemic respiratory failure is mixed with significant failure rates and the need for more advanced management.

- As such, the selective use of this procedure in the ICU for this population may be considered based on best clinical judgement. Patients should be closely monitored for evidence of clinical deterioration.
- If used in patients with suspected or confirmed COVID-19 infection, treatment must be performed in a single patient room with the door closed and with staff using appropriate contact and droplet precautions, including use of N95 respirators.

Non-Invasive Ventilation (CPAP or BIPAP):

- Non-invasive positive pressure ventilation (NIV) may result in aerosolization of respiratory secretions and is considered a continuous AGMP.
- The clinical efficacy of NIV in clinical trials of patients with significant acute hypoxemic respiratory failure is unproven with significant failure rates and the need for more advanced management.
- As such, NIV is not recommended for routine use in suspected or confirmed COVID-19 patients with hypoxemic respiratory failure in the ICU. This does not preclude the selected use of this procedure based on best clinical judgement in patients presenting with patterns more suggestive of cardiogenic pulmonary edema or obstructive lung disease.
- Patients with hemodynamic instability, multi-organ failure, or abnormal mental status are at high risk for failure and should not receive NIV.
- Pro-active intubation under less emergent conditions is the preferred strategy and should be considered.
- If NIV is used in patients with suspected, probable or confirmed COVID-19 infection, NIV treatment must be performed in a single patient room with the door closed and with staff using appropriate contact and droplet precautions, including use of N95 respirators.
- During the COVID-19 pandemic, nocturnal CPAP will not be routinely used for hospitalized patients with OSA since it is an AGMP. Chronic CPAP or NIV should be continued only when deemed essential (i.e. life-sustaining). Consult pulmonary medicine as needed to help define the necessity of use during hospitalization. If therapy is deemed non-essential while the patient is admitted, then consider routinely reassessing to determine when it may safely be resumed.

AHS Scientific Rapid Response Report: Oxygen Therapy Recommendations

Tracheostomy care and management in the non-ventilated patient:

Patients spontaneously breathing via a tracheostomy and remaining on contact and droplet precautions for COVID-19 should:
- Continue to be managed in single patient rooms with use of appropriate PPE.
- Provide humidity as indicated and per current practice.
- Closed suction systems are recommended for these patients.
If single patient rooms are unavailable, patients cohorting may be considered. See guidance. [IP&C Cohorting Recommendations for COVID-19 in Acute Care](#)

**Intubation Guidelines:**

Moderate to severe hypoxemic respiratory failure/ARDS usually requires support with endotracheal intubation and mechanical ventilation. NIV and high-flow oxygen therapies frequently fail to adequately support such patients making intubation necessary. Close monitoring is crucial in order to detect failure of non-invasive support means so that intubation can be performed in a timely and controlled manner using all optimal infection prevention strategies.

1. Endotracheal intubation should, ideally, be performed by the most experienced MRHP available.

2. Minimize number of people involved. **Close the room door.** Nursing and RRT support ideally should be provided by the same individuals assigned to patient.

3. In units with adjustable room airflow rates, increase the rate of airflow (or put the room in “bronchoscopy mode”) prior to intubation.

4. Don full PPE including N95 respirator, face shield, gown and gloves. Proper application of PPE should be verified by an independent observer prior to entry into the patient room.

5. Consider the additional use of goggles given the potential for expectorated secretions to flow around front-covering face shields and contact ocular mucus membranes with coughing and during head turns of the intubator. If goggles are re-used, they must be fully wiped down with disinfectant wipes prior to re-use.

6. Patients with hypoxemic respiratory failure usually have poor oxygenation reserves. Pre-oxygenate as much as possible using non-invasive oxygen. Reserve use of bag-valve-mask ventilation via facemask to situations where non-invasive oxygen delivery is failing (to reduce aerosolization risks).

7. The best pharmacotherapy for induction and intubation will be determined by the MRHP on a case-by-case basis but in general should include strategies that minimize chances of cough or aerosol generation via use of agents inducing deep sedation and often use of neuromuscular blockade when clinically appropriate (e.g. no signs predicting difficult intubation).

8. Consider use of visual technological devices (e.g., video laryngoscope) for the initial attempt at intubation (to reduce the risk of aerosol contact by reducing the need to look directly down the airway); however, MRHP should use the technique most familiar to them that will ensure the greatest probability of successful intubation.

[AHS Scientific Advisory Rapid Evidence Report: Video Laryngoscopy](#)

9. Place in-line suction catheter on in all patients. Use either HMEF or heated humidity systems (if they are fixed integral system of a particular ventilator).
10. In patients not already diagnosed with COVID-19, if sputum samples have not already been collected, collect ETA while all infection control precautions are already in place for intubation.

11. If difficult airway cart or other stand-by equipment is brought to the area, do not bring entire cart/equipment into the room – bring in only the necessary equipment as it is needed.

See additional intubation guidance and tools in Appendix C.

For Intubated Patients:

1. Critically ill COVID-19 patients frequently require advanced ventilator modes and patient management. The following strategies should be considered to support failing gas exchange in COVID-19 infected patients:

   a. Targeted deep sedation +/- neuromuscular blockage (some medications have known shortages – review pharmacy bulletins when selecting sedatives and paralytics).
   b. Elevation of head of bed to 30-45 degrees.
   c. Lung protective ventilator strategies that restrict tidal volumes to 4-8 mL/kg of Ideal Body Weight (IBW).
   d. Limit plateau pressures to ≤ 30 cm H\textsubscript{2}O (exceptions include conditions where there is additional pulmonary extra-parenchymal restrictive physiology such as large pleural effusions, severe obesity or abdominal compartment syndrome) and driving pressures to ≤ 18 cm H\textsubscript{2}O, as applicable.
   e. Allowing permissive hypercapnia.
   f. Optimal titration of PEEP.
   g. Selective use of recruitment maneuvers, as tolerated.
   h. Early consideration for a trial of prone positioning - refer to site specific policy and procedures. See Appendix D for proning summary document.

Educational Resources for Proning During a Pandemic

i. Minimization of fluid accumulation and extra-vascular lung water following initial resuscitation and in patients without hypovolemia via reduction of non-essential fluid intake and correction of positive fluid balance with diuretic therapy or mechanical fluid removal with CRRT.

2. In patients with refractory hypoxemia (e.g., Pa\textsubscript{O2}/Fi\textsubscript{O2} ratio < 150 after attempting all the above strategies), consider the following additional strategies:

   a. Non-conventional modes of ventilation, such as Airway Pressure Release Ventilation (APRV).
b. Inhaled epoprostenol:
   i. Provided per local policy. Dosing 10 – 50 ng/kg/min. An active humidification system is required to use this therapy.
   ii. Use only in intubated patients.
   iii. Patients who do not demonstrate a physiological response (increase in \( \text{PaO}_2 \) of \( \geq 20\% \) from baseline) after 30 minutes should be discontinued from inhaled epoprostenol therapy.
   iv. A daily assessment should be performed in an attempt to discontinue inhaled epoprostenol therapy.

3. If advanced ICU respiratory care (defined as the use of all of the above measures possible to apply) has failed to improve oxygenation or can only be accomplished by applying mechanical ventilation that is not lung protective, consider consulting the ECLS Team (Edmonton for Northern Alberta, Calgary for Southern Alberta).

To initiate a referral:

   a. For Calgary, Central and South Zones, page the on-call CVICU Intensivist at the Foothills Medical Centre (403) 944-1110.
   b. For Edmonton (sites other than UAH) and North Zones, page the on-call Intensivist for the UAH General Systems ICU.
   c. For the UAH site, page the on-call Mazankowski CVICU Intensivist.

An early consultative process is recommended as ideally potential ECLS candidates should be first transferred to the ECLS referral center and then, if deemed suitable candidates, cannulated.

Consider referral to ECLS team when the following criteria are met:

- \( \text{PaO}_2:\text{FiO}_2 \) ratio < 120 mm Hg for > 3 hours with inability to maintain lung protective ventilation (LPV) as defined in section 1 above.
- \( \text{PaO}_2:\text{FiO}_2 \) < 100 mm Hg for > 6 hours even with maintenance of lung protective ventilation.
- An arterial blood pH of < 7.25 with a partial pressure of arterial carbon dioxide [\( \text{PaCO}_2 \)] of \( \geq 60 \) mm Hg for > 6 hours.
- Endotracheal intubation and high-pressure mechanical ventilation for less than 7 days.
- Near maximization of conventional therapies.
- No severe life-limiting chronic illnesses. Expected life expectancy of at least 2 years of independent functioning, should the patient survive.

**ECLS Recommendations for COVID-19**

4. If a patient is not deemed a suitable candidate for ECLS support and continued care is pursued, consider:
   - Permissive hypoxemia - accept SpO2 85-90%, PaO2 50-60.
   - Target Hemoglobin >85 g/L (maximize oxygen carrying capacity).
   - Target temperature <37.5 C (reduce oxygen demand).
5. Bronchodilator delivery should only be provided via MDI and spacer. Nebulizers should not be used.

6. Humidity should be preferentially provided via in-line HME devices or via integral ventilator humidification systems. Avoid use of external active/heated humidity systems unless necessary.

7. Use in-line suction only for all ventilated patients. Avoid open suctioning.

**Extubation Guidelines:**

Extubation of patients is an AGMP. Careful consideration should be given to the safety of HCWs during the extubation procedure and to reduced reintubation rates.

1. Ensure readiness for extubation
   - Extubate from spontaneous or pressure support with low PEEP.
   - FiO2 ≤ 0.50.
   - Patient should be ready for extubation onto low-flow oxygen.
   - Per usual practice, ensure cuff leak.

2. Apply PPE per AGMP.

3. Two staff members are recommended during extubation to monitor safety given the time to apply PPE should any assistance be required.

4. Strategies should be employed to minimize coughing
   - Oral suctioning may be performed with care taken not to precipitate coughing.
   - Medication to minimize coughing may be employed such as use of intravenous opioids, lidocaine or dexmedetomidine.

5. Post ventilation handling of ventilator: Follow site specific protocols for cleaning and disposal.

**Medical Care**

Goals of care discussions should occur early in admission consistent with our regular practice. [Streamlined Goals of Care Designation decision-making for COVID-19](#)

Other standard practices of medical care will apply such as nutrition in the ICU and ventilator acquired pneumonia prevention protocols.

Currently there are no robust evidence-based effective direct antiviral therapies for the treatment of the novel coronavirus, SARS-CoV-2, and supportive care remains the mainstay of therapy for infected individuals. For patients presenting with an ILI where SARS-CoV-2 is one possible etiology, it is important to recognize the possibility of
additional common viral and bacterial pathogens to underlie the patient’s presentation, even in the presence of exposure to COVID-19 infected individuals or relevant travel exposures.

Current Guidance for the Management of Adult Hospitalized Patients with COVID-19

Microbial Testing

Even in patients with proven COVID-19 infection, particularly in patients with severe disease, bacterial and/or other viral co-pathogens may be present.

All patients evolving severe illness should be tested for the full spectrum of respiratory viruses (including SARS-CoV-2) and bacterial pathogens.

This should include:

i In all patients, an NPS and/or ETA for respiratory viruses (including SARS-CoV-2) (see admission testing Section C above).

ii In intubated patients, an ETA sample for bacterial culture.

iii For non-intubated patients NPS will be used for diagnosis of SARS-CoV-2, and in those able to produce sputum, expectorated sputum can be sent for bacterial culture. Sputum induction is not recommended in non-intubated patients (to reduce exposure risks).

iv Blood cultures x 2 drawn from separate lines/sites.

v Sampling of pleural fluid as appropriate if present is significant quantities.

Bronchoscopy solely for the purposes of microbial sampling in otherwise uncomplicated patients is not recommended (unproven benefit; high risk procedure). If there is a clinical possibility of other more unusual pathogens (e.g., as in an immunosuppressed patient), consideration could be given to performing bronchoalveolar lavage (BAL) recognizing that bronchoscopy is an AGMP. If necessary, bronchoscopy should be performed only in intubated patients and avoided in non-intubated patients with COVID-19 in order to minimize the risk of aerosolization.

Empiric Antimicrobial Therapy

Antibiotics will generally have a limited role in managing patients with proven COVID-19 though they are indicated for Initial empiric management of patients with severe pneumonia while COVID-19 is being confirmed and bacterial superinfection is being excluded.

Patients evolving severe illness should be empirically treated with intravenous antibacterials along with consideration for oseltamivir (seasonally depending on circulation of influenza) pending results of initial microbial testing. Appropriate antibacterials should
take into consideration patient presentation (isolated respiratory vs more generalized illness), allergies, prior or high risk for colonization with ARO (e.g., MRSA), local microbial resistance patterns and comorbid disease that might influence antibiotic use (e.g., conduction delay). As per current guidelines for community-acquired pneumonia management, initial empiric antibacterial coverage should include an agent to cover atypical microbes (e.g., macrolide, respiratory quinolone or tetracycline) and typical bacterial species. Initial empiric therapy should be de-escalated or discontinued as microbiology results return as appropriate.

COVID-19 Specific Antiviral Therapy

As of the date of this guideline, there are no approved or evidence-informed therapies proven in clinical trials directed towards SARS-CoV-2. There are numerous clinical trials underway in many countries and one expects new treatment information to evolve over time. It is important to check the status of directed anti-viral therapies via AHS guidance:

COVID-19 Scientific Advisory Group Rapid Response Brief: Remdisivir

In addition, the following agencies may provide up to date guidance on anti-viral therapies:

Suitability for participation in clinical trials should be considered.

Systemic Corticosteroids

The RECOVERY (and other) trials have provided new rigorous evidence to support use of treatment with dexamethasone 6 mg delivered intravenously or enterally once daily for up to 10 days to reduce 28-day mortality in patients with COVID-19 who are receiving respiratory support. This recommendation is limited to patients who are receiving respiratory support (i.e., supplemental oxygen and/or invasive mechanical ventilation) with the greatest mortality benefit seen in those requiring invasive mechanical ventilation.

WHO Rapid Evidence Appraisal
RECOVERY Trial: Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report
REMAP-CAP Trial: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Systemic steroids may also be of value for other clinical indications such as severe septic shock or ILI triggered asthmatic exacerbation.
Fluid Management

Following initiation resuscitation, use conservative fluid management in patients with COVID-19 when there is no evidence of shock or overt hypovolemia. Patients with COVID-19 should be treated cautiously with intravenous fluids, because aggressive fluid resuscitation and fluid accumulation may worsen oxygenation. Hypotonic fluids, starches and albumin should generally be avoided. Minimization of fluid accumulation and extravascular lung water via reduction of non-essential fluid intake and mitigation of fluid accumulation with diuretic therapy or mechanical fluid removal with CRRT should be applied, as applicable.

Immune Modulating Therapies

Severe COVID disease is often associated with ARDS and cytokine release. There is an evolving evidence base exploring the use of IL-6 receptor antagonists for the treatment of patients with severe COVID-19 disease.

AHS has approved tocilizumab for the treatment of severe COVID-19 pneumonia, restricted as follows:

1. Patient was admitted to hospital due to COVID-19 seven or fewer days ago OR patient developed symptoms due to hospital-acquired COVID-19, while in hospital for other reasons, seven or fewer days ago

AND

2. The patient is experiencing significant respiratory failure, due to COVID-19 pneumonia, which requires:
   a. Invasive or non-invasive ventilation (e.g. Continuous Positive Airway Pressure or Bilevel Positive Airway Pressure) OR
   b. Supplemental oxygen to achieve a minimal SpO2 of 90%, in the form of one of the following:
      i. Heated high flow oxygen with FiO2 > 0.5 (e.g. Optiflow, Airvo)
      ii. Oxygen delivered via nasal prong at a rate > 6 L/minute
      iii. Mask delivered oxygen with FiO2 > 0.5 (e.g. non-rebreather or Venturi mask)

AND

3. No more than 24 hours has elapsed since initiation of ventilation as defined above or since the patient met the oxygen thresholds stated above

AND

4. The patient has not received another dose of tocilizumab for the same indication at any point during their current hospitalization.
The use of tocilizumab as above is restricted to a SINGLE DOSE per patient, based on the following weight-based dosing:

- 40 or less kg: 8 mg/kg
- 40 kg to 65 or less kg: 400 mg
- 65 kg to 90 or less kg: 600 mg
- Greater than 90 kg: 800 mg

**Venous Thromboembolism (VTE) Prevention**

Patients admitted to critical care with COVID-19 are at significant risk of thrombotic complications such as VTE. Standard prevention therapy is recommended for all COVID-19 positive patients with a preference for low molecular weight heparin (LMWH) administered at standard doses. Pneumatic Compression Stockings (PCS) should be used when pharmacological interventions are contraindicated.

[Scientific Advisory Group - Rapid Evidence Brief - VTE in COVID-19](#)
[Scientific Advisory Group - VTE Infographic](#)

**Vitamin D**

There is no high-quality evidence to suggest vitamin D at supplemental or higher doses is effective in the prevention or treatment of COVID-19.

[Scientific Advisory Group - Rapid Evidence Brief - Vitamin D](#)

**Clinical Trials**

Consideration should be given to enrollment in any locally active clinical trials (epidemiologic or treatment related) if available. Contact the local research coordinator or MRHP as appropriate.

**Handling of Patient Care Items and Equipment**

1. Use disposable patient equipment when possible.
2. Dedicate re-useable equipment for single-patient use only and until discharge.
3. If reusable equipment cannot be dedicated for a single patient use, clean and disinfect it between patients. Handling, Cleaning & Disinfecting Mobile DI Devices and Stethoscope Use for Patients on Contact & Droplet Precautions and Stethoscope and Eye Protective Goggle Cleaning Visual Procedure.
4. All rooms should contain a dedicated linen bag; double bag only if leaking.
5. Do not share items that cannot be cleaned and disinfected.
6. For shared computers, laptops and tablets, follow Recommendations for Using Mobile & Electronic Devices for Contact & Droplet Precautions including COVID-19.
7. Used meal trays and dishes do not require special handling. Disposable dishes and utensils are not required.
8. Special handling of linen or waste is not required: general waste from patients on additional precautions is not biomedical waste. Tip Sheet for Acute Care Patients and Designated Family/Supports during COVID-19 Pandemic.

9. Paper is not a means of transmission. Handle all paper with clean hands; clean any shared items (like chart binders, pens or binders) with a low-level disinfectant wipe.

**Environmental Cleaning**

### Enhanced Environmental Cleaning during COVID-19

1. Cleaning & disinfection are a shared responsibility by both healthcare workers and Environmental Services. Consider assigning designated staff to complete enhanced environmental cleaning.

2. Routine practices, which include cleaning and disinfection of surfaces, is important to control the spread of COVID-19.

3. AHS provided disinfection products are effective against COVID-19.

4. Any high-touch surfaces that are visibly soiled should be immediately cleaned and disinfected. All cleaning should be a 2-step clean.

5. Remove curtains that are not necessary from patient areas.

6. After discharge, transfer or discontinuation of contact and droplet precautions apply discharge/transfer isolation cleaning protocol including changing curtains on discharge/transfer.

7. Additional precaution signs should not be removed until both patient’s personal hygiene and environmental cleaning have been completed.

**Staff Tips: COVID-19 Personal Clothing and Cleaning**

**Surfaces Bedside Computers and Electronic Devices**

**Key Points for Ready-to-Use Disinfectant Wipes**

**Cleaning and disinfecting the iPad Patient-Family Virtual Visitation**
Appendix A

Putting on (Donning) Personal Protective Equipment (PPE)

1. **HAND HYGIENE**
   - A. Using an alcohol-based hand rub is the preferred way to clean your hands.
   - B. If your hands look or feel dirty, soap and water must be used to wash your hands.

2. **Gown**
   - A. Make sure the gown covers from neck to knees to wrist.
   - B. Tie at the back of neck and waist.

3a. **Procedure/Surgical mask**
   - Secure the ties or elastics around your head so the mask stays in place.
   - Fit the moldable band to the nose bridge. Fit snugly to your face and below chin.

3b. **N95 respirator**
   - There are different styles of N95 respirators (pictured below). They include:
     - a. molded cup
     - b. duckbill
     - c. flat-fold
     - d. v-fold
   - All styles have the same basic steps for donning; molded cup and duckbill are pictured below. Refer to the manufacturer for specific donning instructions.

4. **Eye protection or face shields**
   - A. Place over the eyes (or face).
   - B. Adjust to fit.

5. **Gloves**
   - A. Pre-stretch both top and bottom straps before placing the respirator on your face.
   - B. Cup the N95 respirator in your hand.
   - C. Position the N95 respirator under your chin with the nose piece up. Secure the elastic band around your head so the N95 respirator stays in place.
   - D. Use both hands to mold the metal band of the N95 respirator around the bridge of your nose.
   - E. Fit check the N95 respirator.

www.albertahealthservices.ca

May 2014
# Appendix B

## Taking off (Doffing) Personal Protective Equipment (PPE)

### 1. Gloves

- **A** Grasp the outside edge of the glove near the wrist and peel away from the hand, turning the glove inside-out.
  - Hold the glove in the opposite gloved hand.
- **B** Slide an ungloved finger or thumb under the wrist of the remaining glove.
- **C** Peel the glove off and over the first glove, making a bag for both gloves.
  - Put the gloves in the garbage.

### 2. Hand Hygiene

- **A** Using an alcohol-based hand rub is the preferred way to clean your hands.
- **B** If your hands look or feel dirty, soap and water must be used to wash your hands.

### 3. Gown

- **A** Carefully unfasten tie.
- **B** Grasp the outside of the gown at the back of the shoulders and pull the gown down over the arms.
- **C** Turn the gown inside out during removal.
  - Put in hamper or, if disposable, put in garbage.

### 4. Hand Hygiene

- **Clean your hands.** (See No. 2)
- Exits the patient room, closes the door and cleans your hands again.

### 5. Eye Protection or Face Shield

- Handle only by headband or ear pieces.
- Carefully pull away from face.
- Put reusable items in appropriate area for cleaning.
- Put disposable items into garbage.

### 6. Mask or N95 Respirator

- Draw the mask slightly and carefully remove the mask from your face by touching only the ties or elastic bands.
- Start with the bottom tie, then remove the top tie.
- Throw the mask in the garbage.

There are different styles of N95 respirators but all styles have the same basic steps for doffing.

### 7. Hand Hygiene

- **Clean your hands.** (See No. 2)

---

May 2014

---

www.albertahealthservices.ca
Appendix C

ILI - COVID-19 Airway Management Best Practice Considerations
V10, Sept 2, 2020

Preparation
1. PPE. Don full PPE including N95 respirator, goggles or face shield, gown and gloves. Proper application of PPE should be verified by an observer prior to patient contact.
2. Early airway assessment for predictors of difficulty and consultation as necessary.
3. Consider early, controlled intubation—patient trajectory and clinical judgment are important. Avoid NIV, HHHPO and other AGMP as able.
4. Minimize staff exposure:
   a. Minimize personnel in the room as able.
   b. Negative pressure room with anteroom if available (or neutral pressure room with door closed).
   c. Ensure HMEF is between the mask and BVM at all times.
5. Intubation should be performed by an experienced practitioner to optimize first pass success.
6. Prepare necessary equipment and drugs OUTSIDE of room and communicate intubation plan.

Suggested Roles and Organization

<table>
<thead>
<tr>
<th>Patient Room</th>
<th>Outside Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitor</td>
<td>Recorder/PPE monitor</td>
</tr>
<tr>
<td>ICU Intubator</td>
<td>DAM Cart</td>
</tr>
<tr>
<td>Airway Equipment</td>
<td>RT 1</td>
</tr>
<tr>
<td>Ventilator</td>
<td>RT 2 / Runner</td>
</tr>
<tr>
<td>Nurse</td>
<td>Backup Intubator / Runner</td>
</tr>
<tr>
<td>Anteroom</td>
<td></td>
</tr>
</tbody>
</table>

Intubation Plan
- Optimize patient and intubator positioning; consider need for Trendelenburg.
- Optimize pre-oxygenation using nasal prongs with 5L/min O2 (up to 15L/min as necessary) AND tight seal BVM with ≥ 15L/min O2 to keep reservoir inflated and PEEP valve = 5 cm H2O.
- Reserve 2-person 2-handed BVM manual ventilation for situations when O2 delivery is failing.
- Video laryngoscopy is preferred where available as Plan A to keep intubator farther from the patient.
- Best induction pharmacotherapy determined by MRHP on case-by-case basis to minimize chance of cough and aerosol generation.
- If no contraindications, Modified RSI (avoid coughing and facilitate first pass success) and leave nasal prongs with O2 in place for anaerobic oxygenation:
  - Use higher mg/kg dose of muscle relaxant to ensure rapid onset of optimal intubating conditions (allow 1 minute for onset of adequate muscle relaxation):
    - Rocuronium 1.5 mg/kg (IBW) or Succinylcholine 1.5 mg/kg (TBW)
  - If SpO2 < 70% begin 2 person 2 handed BVM manual ventilation with an OPA
  - Wait until cuff inflated post-intubation before ventilating.

Post-Intubation
- Confirm ETT position with ETCO2 and CXR
- Closed suction system; avoid circuit disconnections and clamp ETT for planned disconnections.
- Lung protective ventilation strategy (6-8 mL/kg VT IBW; Pplat < 30 cm H2O; Optimal PEEP).
- Strategies for failing gas exchange: deep sedation and paralysis; permissive hypercapnia; prone positioning.
- Property doff PPE using a spotter / PPE buddy
- Maintain Droplet and Contact isolation

AGMP = arterial generating medical procedures; BVM = bag valve mask; HHHPO = heated humidified high flow oxygen (AMBO, Optiflow); RSI = rapid sequence intubation; IBW = ideal body weight; MRHP = most responsible healthcare provider; NIV = non-invasive ventilation; OPA = oro-nasal endotracheal intubation; SpO2 = oxygen saturation; TBW = total body weight.

Used with permission - Sept 2020, Department of Critical Care Medicine – Calgary Zone
Difficult Airway Management in an Unconscious Patient

PLAN A
Initial Intubation Strategy

Optimized primary approach unsuccessful

Does face mask or Supraglottic device (SGD) ventilation maintain adequate oxygenation?

YES
Call for help and DAM cart if needed

NO
No time

EMERGENCY
Can’t Intubate
Can’t Oxygenate

CALL for help STAT

One attempt at SGD if not already tried

Fails

Surgical airway / Front of neck access

PLAN B
Secondary Intubation Strategy

Up to two further intubation attempts:

Alternative device

Experienced operator

Proceed directly to Exit or Emergency

EXIT
Optimize Oxygenation

Failed intubation

Buy time with face mask or SGD oxygenation

Call for additional expert help

Awaken patient if feasible

If oxygenation cannot be maintained proceed to Emergency

Used with permission - Sept 2020, Department of Critical Care Medicine – Calgary Zone
Appendix D

Provincial Guidance: Prone Positioning for Adult COVID-19 Patients

Background

- SARS-CoV-2 infection can result in Coronavirus Disease–19 (COVID-19).\textsuperscript{1,2} While the majority of patients are asymptomatic or have mild disease,\textsuperscript{3} approximately 14\% develop more severe disease and/or Acute Respiratory Distress Syndrome (ARDS).\textsuperscript{3}
- Mechanical ventilation in the prone position for patients with ARDS is a technique to improve oxygenation and lung recruitment. Findings from clinical trials have shown this can improve V/Q matching, reduce ventilator induced lung injury and improved survival.\textsuperscript{4,5}
- As part of the management of critically ill COVID-19 patients with ARDS, the WHO guidelines recommend those patients receiving mechanical ventilation should be considered for a trial of prone positioning.\textsuperscript{6}
- Patients with moderate to severe ARDS (as per the Berlin definition) who are placed in the prone position may need to be maintained in this position on average for 14-16 hours per day and often for 4-6 days to derive clinical benefit.

Indications

- Patients should be considered for prone positioning if
  - Patient is adequately sedated and paralyzed AND
  - Lung protective ventilation strategies are being applied AND
  - Evidence of bilateral airspace disease suggestive of ARDS AND
    - Persistent PF ratio ≤ 150 with FiO2 ≥ 0.60 for > 4 hours (suggest prone position)
    - Persistent PF ratio ≤ 100 with FiO2 ≥ 0.60 for > 4 hours (recommend prone position)

Contraindications

- There are very few absolute contraindications:
  - Pregnancy – third trimester
  - Spinal cord injury – unstable
  - Open abdomen (fascia not closed) or open chest
- Patients with whom extra caution should be exercised prior to prone positioning:
  - Recent tracheostomy
  - Unstable extra-axial fractures
  - Ventricular assist devices or intra-aortic balloon pump

Timing

- Prone positioning of a patient should always occur in a planned fashion
  - Patients benefit most from prone positioning when used for 14-16 consecutive hours per day
  - The initial decision to prone should be made early, in consideration of clinical
indicators and staff availability
  o Efforts should be made to plan subsequent prone and supine (unproning) positioning to occur during daytime hours (or when staffing is maximal)
• Unplanned prone positioning may be done when a patient acutely deteriorates. This may be more common in the first 24 hours of patient admission to the intensive care unit.

Requirements
• Team size will be determined by each site and guided by the size of the patient and members of the prone positioning team
• The attending physician or assigned delegate must be present for the initial prone positioning procedure.
• The attending physician or assigned delegate must always be aware of any subsequent prone/supine positioning maneuvers, and available for support as needed. Follow local processes.
• At a minimum prone positioning of a patient can be accomplished by 5 team members
  o One respiratory therapist – primary responsibility is management of the airway
  o One registered ICU nurse – primary responsibilities are the lines, catheters, tubes and drips
  o Three additional healthcare workers
    ▪ Can be ICU or non-ICU staff including RRT/RN/HCA/allied health workers/physicians.

Equipment
• 2 – Flat sheets
• 1 – Proning head cushion and one pillow case to cover cushion/plastic bag
• 1 – Absorbent pad
• 3 – pillows
• Skin protection dressing (duoderm, mefix, etc.)
• Proneing checklist

Care of the Proned Patient
• Refer to existing local policy and procedure for detailed information
• Patients may be in prone position for up to 20 hours per day (of which at least 14-16 hours should be continuous, as directed by attending physicians’ orders)
• Continue with regular clinical, physiologic and laboratory assessments:
  o Follow oxygenation and hemodynamic status closely to monitor for deterioration – as patients can experience transient deterioration in gas-exchange shortly after proning prior to improvement
  o Chest and heart sounds can be assessed by slipping stethoscope under patient’s chest (if using a special care bed this will be easier if air pressure is decreased in the area to be assessed)
• Minimize sedation and paralytics as patient condition allows, as ordered by the attending physician
• Head turns and arm repositioning are done q2h to prevent skin break down, contractures, and nerve compression
• Use a support under the patients face (e.g., gel horseshoe, foam cushion, or folded pillow) to ensure the downward eye is free from pressure. Apply eye lubrication q2h to prevent eye damage.
• Keep the bed in reverse Trendelenburg whenever possible to prevent venous congestion of the head and neck.
• Avoid over extension of the neck with positioning. Facilitate PT/PROM exercises as tolerated.

**FAQs**

• **CRRT** – Can be run while in prone position. The patient should have an easily visible line (jugular).
• **CPR** – CPR can be performed while in the prone position while awaiting team to flip.
• **Paralysis** – Neuromuscular blockade is strongly suggested prior to a trial of prone positioning.
  *Femoral lines* – Caution needs to be exercised if patients have venous or arterial femoral lines as these are not visualized while patients are in prone position.
Appendix E

Conservation of Personal Protective Equipment (PPE) in Critical Care Areas.

Goal: To conserve use and reduce wastage of PPE in Critical Care areas while maintaining safety for all members of the health care team.

- PPE conservation strategies are to be initiated immediately.
- PPE usage should be restricted to direct patient care use only.
- PPE should not be used for simulation, orientation and education purpose unless it is expired.

Considerations to maximize time spent in isolation room

1. Reduce doffing of PPE and leaving room to collect supplies.
   - Keep stock in rooms that is not excessive.
   - RN and RRT to discuss patient care supply requirements during shift handover.
   - Staff to determine required supplies before going into room for care and procedures.
   - Use call bell for supply runners rather than leaving isolation.
   - Utilize supply runners as ‘clean staff’ to assist isolation staff to fetch required supplies. This could be staff that has been redeployed to critical care including students.

2. Group documentation together.
   - Utilize existing computers in room for charting.
   - Charting does not need to be completed in real time.
   - Utilize whiteboards or glass doors for interim documentation with a dry erase marker for later translation into the health record.
   - If staffing allows, utilize a staff to transcribe outside the room while care provider remains in the room.

3. Adjust room temperature to accommodate staff comfort levels.

Considerations to Minimize staff entering isolation room

1. Minimize staff entering the room
   - Reconfigure patient room to improve the line of vision to patient, ventilator, drainage systems, monitor and other pertinent equipment.
   - RRT & RN to share tasks and responsibilities and determine if it is necessary for 2


staff members to enter patient room.

- Staff already in isolation should be utilized to complete ECG and blood draws vs a lab tech entering.
- Adjust alarm parameters to reduce non-relevant alarms.
- Utilize bed functions such as turn assist, rotation, percussion and vibration.
- Utilize the function of overhead lifts and repositioning slings to reduce the number of staff for repositioning. Single person techniques should be reviewed and utilized in possible.

- During prone positioning, only team members directly involved in the turn need to be in the room.
- Minimize patient washes and linen changes if appropriate.
- RN & RRT to remove garbage when full to reduce frequency of housekeeping entering the room. Garbage must be properly disposed of.

2. During daily multidisciplinary rounds have the team determine the most appropriate minimum assessment/interventions required to deliver care for stable patients.

- Areas of frequent RRT & RN assessment that should be evaluated are:
  - Patients’ physical assessment.
  - Vital Signs, neuro vitals & glucometers,
  - Ins and outs
  - Foley and Flexi seal usage
  - RASS goals
- Bloodwork and ABGs.
  - Minimize the frequency of blood draws and review at rounds each day
  - Bundle order times of required bloodwork
  - Before redrawing determine if required order can be added to previously drawn bloodwork.
- Do not order routine CXR or ECG – order only as needed when clinically indicated.
- Minimize off unit procedures or interventions. Review the need for off – unit care with the care team. Deliver care at the bedside as much as possible.
- Nursing in collaboration with pharmacy to adjust medication administration times so that regularly scheduled medications can be administered in a cluster vs staggered administration. Suggest alignment with feeding tube water flushes.
- Physician assessments should be kept to one per 24 hours unless clinical indication requires further assessment. This includes Residents, Fellows and Attending Physicians.
3. To reduce the frequency of entry into isolation room consider utilizing MRI tubing as an extension to regular IV tubing and have IV pumps located outside of the patient room.

Caution and Guidelines

- ACLS and critical medication bolus cannot be infused via extension tubing.
- Patients who are highly dependent on the infusion to achieve set RASS and hemodynamic goals should have infusions in the room.
- Lines must be marked with color tabs to make them visible.
- Lines should be located in areas that are not going to result in injury to staff or dislodgment of line.
- Extension tubing can only be connected to central line.
- Line cannot be touching the floor.
- MRI tubing must be labeled with all medications infusing through it.
- Ensure that lines are positioned to reduce risk of occlusion.
- Use triple lumens or manifolds to connect medications before attaching to MRI tubing.
- MRI tubing must be primed with all medications prior to connection.